Nanopharmaceutics

Nanopharmaceutics is a clinical-stage biotech focused on enhancing drug delivery through nanoparticle formulations, primarily for BCS Class II and IV small molecules. The company has a pipeline of nine clinical-stage programs across oncology, CNS, metabolic, and infectious disease indications, supported by a leadership team with a long track record in product development and government contracting. While privately held, it operates as a subsidiary of the public entity TRON Group Inc. (OTC: TGRP) and leverages affiliate Alchem Laboratories for discovery capabilities, positioning itself to address significant unmet needs in targeted drug delivery.

Expertise in nanoparticle and fine-particle formulations to improve bioavailability, stability, and targeted delivery of hard-to-formulate BCS Class II and IV small molecule drugs across oral, topical, and injectable routes.

The company operates in the highly competitive nanoparticle drug delivery sector, competing against large pharma internal efforts, pure-play platform companies (e.g., Arrowhead, Moderna for nucleic acids), and other specialty formulators. Differentiation relies on specific formulation expertise, intellectual property, and successful clinical translation across diverse drug classes.